CSL share price lifts amid US$4b debt raise

The biotech giant's shares are on the rise after the company announced details of a debt raise.

| More on:
A man in suit and tie is smug about his suitcase bursting with cash.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price is in the green after the company announced details of its bond issue
  • The US$4 billion will be used to fund the acquisition of Vifor Pharma
  • This deal is planned to grow CSL’s earnings into new areas

The CSL Limited (ASX: CSL) share price is edging higher in early trading after the ASX healthcare share revealed details of its debt funding for its acquisition of Vifor Pharma Ltd.

At the time of writing, CSL shares are swapping hands for $265.66 apiece, a gain of 0.44%.

The biotechnology giant intends to use the cash proceeds from the offering to partially finance the proposed acquisition of Vifor, which the company announced in December 2021. Some of the money will also be used for general corporate purposes.

What did CSL announce?

The CSL share price is gaining after the company revealed it has priced US$4 billion of bonds in the US market. The notes were issued by CSL Finance and are guaranteed by the parent company.

There were six different tranches of notes:

  • US$500 million of 5-year notes with an interest rate of 3.85%
  • US$500 million of 7-year notes with an interest rate of 4.05%
  • US$1 billion of 10-year notes with an interest rate of 4.25%
  • US$500 million of 20-year notes with an interest rate of 4.625%
  • US$1 billion of 30-year notes with an interest rate of 4.75%
  • US$500 million of 40-year notes with an interest rate of 4.95%

Management commentary

CSL chief financial officer Joy Linton said:

We are pleased with the outcome of the bond issue from both a demand and pricing perspective. It also provides depth and flexibility for our long-term capital management program.

The strong support shown by investors towards our inaugural US dollar bond issue reflects positively on our track record of disciplined financial management, as well as confidence in our strategy to invest in our leading therapeutic capabilities and generate sustainable growth.

Vifor acquisition

CSL said the regulatory process for the Vifor Pharma acquisition is on track to be completed by June 2022.

The company has also completed a A$6.3 billion institutional placement to fund the deal.

CSL describes Vifor Pharma as a global specialty pharmaceutical company with leadership in renal disease and iron deficiency.

CSL also said it would enhance CSL's patient focus and ability to protect the health of those facing a range of rare and serious medical conditions. It also expands CSL's presence in the rapidly growing nephrology market.

In terms of the financial side, CSL said it would add to revenue and cash flow. It was expecting to be able to achieve US$75 million of pre-tax cost synergies over three years after the deal is completed.

Management expects the deal to add to underlying net profit after tax (NPAT) in the low-to-mid-teens in the first full year of CSL ownership, including the cost synergies. This could be helpful for the CSL share price.

One of the latest ratings comes from Citi. It rates CSL as a buy with a price target of $335. That implies a potential upside of around 26%.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three happy girls on jumping motion with inflatable mattresses at the beach.
Share Gainers

3 ASX All Ords shares leading the charge in 2025

These ASX All Ords shares have soared 16% to 37% already in 2025.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

3 ASX 200 healthcare stocks with 'strong return potential' in 2025

A leading investment manager expects 2025 will be a good year for these ASX 200 healthcare companies.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Why are Mesoblast shares in a trading halt?

The biotech company requested a trading halt before the market open on Friday. Here's why.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

ASX All Ords stock rockets 18% on FDA clearance

This stock is making very healthy returns on US news.

Read more »

rising medical asx share price represented by excited doctors dancing in ward
Healthcare Shares

Up 77% in a month! What's going on with the Mesoblast share price?

This stock has blown the lights out in recent weeks...

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Guess which ASX healthcare stock is up 31% on big news

What is getting investors excited on Tuesday? Let's find out.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Healthy gains: 5 best ASX 200 healthcare shares of 2024

Four of the five best-performing ASX 200 healthcare stocks of 2024 more than doubled in value.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why did the CSL share price go backwards in 2024?

CSL shares closed out 2024 in the red. But why?

Read more »